Division of Regulus Therapeutics Inc.
Latest From Regulus microMarkers
Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Regulus Therapeutics Inc.
- Senior Management
- Kleanthis Xanthopoulos, PhD, Pres. & CEO
- Contact Info
Phone: (888) 734-8587
3545 John Hopkins Ct., Ste. 210
San Diego, CA 92121-1121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.